SARS-CoV-2 Antibody Pairs for Sandwich Assays

Sandwich assays use two monoclonal antibodies to improve the specificity of antigen detection assays, by requiring detection of a target via two distinct epitopes. The bridged conformation of the final immune complexes also underpins the design of lateral flow immunoassays, or rapid tests.

Anti-Spike sandwich ELISAs using Sb#68 (Ab02017) as the capture antibody and either Sb#15 (Ab02013) or CV30 (Ab02019) as the detection antibody.

The demand for SARS-CoV-2 matched antibody pairs is currently high due to worldwide efforts to develop diagnostic tests for the COVID-19 pandemic. However, it can often be challenging to find matched antibody pairs from single suppliers, resulting in complicated (and sometimes unstable) supply chains.

At Absolute Antibody, we are pleased to present a selection of SARS-CoV-2 matched antibody pairs. All antibodies are available engineered into multiple species and formats to allow differential detection. Moreover, chimeric human versions are available to counteract false positives and false negatives from heterophile antibodies (e.g., HAMA). The antibodies are all recombinantly produced for ensured batch-to-batch reproducibility and guaranteed long-term supply.

SARS-CoV-2 matched antibody pairs in our collection include:

• Anti-Receptor Binding Domain Antibodies Sb#15 and Sb#68
• Anti-Receptor Binding Domain Antibodies CV30 and Sb#68
• Anti-S1 Antibodies CR3022 or CV1 paired with anti-RBD binders Sb#15, Sb#68 or CV30
• Anti-Nucleocapsid Antibodies CR3018 and CR3009

The anti-SARS clones CR3022, CR3018 and CR3009 were all shown to have high affinity for the SARS-CoV-2 virus, and they are now being used as serological controls in COVID-19 diagnostic assays. The anti-RBD binders Sb#15 and Sb#68 were generated as synthetic nanobodies by the University of Zurich and then engineered and recombinantly produced through a partnership with Absolute Antibody. The clones CV1 and CV30 are SARS-CoV-2 neutralizing antibodies originally derived from COVID-19 patients by Fred Hutchinson Cancer Research Center.

If you want to find out more about our recombinant coronavirus antibodies, or would like to discover how antibody engineering can be used to improve performance in antigen detection assays, please contact us. Our team specializes in antibody engineering, and we work with diagnostic developers worldwide to overcome their assay design challenges by reformatting antibodies into different species, isotypes and subtypes for recombinant production.